ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some

EZH2 inhibitors is a budding drug class—already with one approved therapy and a few in the pipeline—and Pfizer is the largest pharma to add the tool to its clinical belt. And phase 1 data of Pfizer's asset points toward a positive safety profile, with glimpses of benefit for some cancer patients, though not all tested may be able to count on the therapy.